Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670230 | 1.00 | KMT2A (0.56) | KMT2AFABP5FABP7CASP3EGFR | |
| SCHEMBL13329984 | 0.96 | KMT2A (0.58) | KMT2AFABP5FABP7CASP3EGFR | |
| SCHEMBL5148054 | 0.95 | KMT2A (0.60) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL7853751 | 0.92 | KMT2A (0.55) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29989813 | 0.92 | KMT2A (0.55) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL12703322 | 0.90 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL12703276 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| Succinic Acid SCHEMBL27739367 | 0.88 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL14656652 | 0.87 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL23156989 | 0.86 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939959-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Nissan Chemical Corporation (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889843-B2 | Nucleic acid synthesizing dimer amidite and nucleic acid synthesizing method | APTA BIOSCIENCES LTD. (GB) | 2014-11-18 | — | — | US | disclosed |
| US-8889843-B2 | Nucleic acid synthesizing dimer amidite and nucleic acid synthesizing method | APTA BIOSCIENCES LTD. (GB) | 2014-11-18 | — | — | US | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-8299225-B2 | Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid | FUJITSU LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-7910726-B2 | Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid | FUJITSU LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910726-B2 | Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid | FUJITSU LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | FUJITSU LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | FUJITSU LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1042279-B1 | SUBSTITUTED BETA-ALANINES | AVENTIS PHARMA LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6352977-B1 | ALANINE WITH PRODRUGS | AVENTIS PHARMA LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-1042279-A1 | SUBSTITUTED BETA-ALANINES | Aventis Pharma Limited (GB) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033789-A1 | SUBSTITUTED β-ALANINES | AVENTIS PHARMA LIMITED (GB) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KMT2A 4608/4885FABP5 2565/4885FABP7 3166/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | KMT2A 4201/4885FABP5 1216/4885FABP7 712/4885 |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | NSUN2, RNMT, ADAR | KMT2A 595/4885FABP5 3103/4885FABP7 3083/4885 |
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | ADAR, RNGTT, ATIC | KMT2A 2434/4885FABP5 2140/4885FABP7 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.